55
Participants
Start Date
January 4, 2022
Primary Completion Date
November 21, 2024
Study Completion Date
July 5, 2026
Blood sample collection
"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
Biopsy
A tumor biopsy will be performed at 2 months after enrollment.
Centre georges-François Leclerc, Dijon
Centre Hospitalier Universitaire de Besançon, Besançon
Centre Léon Bérard, Lyon
Hôpital Privé Jean Mermoz, Lyon
Hôpital Saint Louis, Paris
Hôpital Franco-Britannique, Levallois-Perret
Hôpital Nord Franche-Comté, Montbéliard
Centre Antoine Lacassagne, Nice
CHU de Poitiers, Poitiers
CHU Robert Debré, Reims
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Centre Hospitalier Universitaire de Besancon
OTHER